BCL2 and cancer: An alternative target of focus is B‐cell lymphoma (BCL)‐2, which has been shown to be overexpressed in >66% of BCP‐ALL cases compared to normal bone marrow (NBM) donors23 and is associated with oncogenesis in several cancers.24, 25